Pharmacodynamics of cidofovir for vaccinia virus infection in an in vitro hollow-fiber infection model system

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 1, 2009, Pages 129-135

  McSharry, James J ^a   Deziel, Mark R ^a   Zager, Kris ^a   Weng, Qingmei ^a   Drusano, George L ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; PROBENECID;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; HELA CELL; HOLLOW FIBER; HUMAN; HUMAN CELL; IN VITRO STUDY; INFECTION PREVENTION; NEPHROTOXICITY; PRIORITY JOURNAL; SMALLPOX VIRUS; VACCINIA; VIROGENESIS;

ANTIVIRAL AGENTS; CYTOSINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HELA CELLS; HUMANS; MODELS, THEORETICAL; MONKEYPOX VIRUS; PHOSPHONIC ACIDS; POXVIRIDAE INFECTIONS; SMALLPOX VACCINE;

EID: 59749085410     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00708-08     Document Type: Article

References (45)

1. Baker, R. O., M. Bray, and J. W. Huggins. 2003. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antivir. Res. 57:13-23.
2. Bilello, J. A., G. Bauer, M. N. Dudley, G. A. Cole, and G. L. Drusano. 1994. Effect of 2′,3′-didehydro-3′-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies. Antimicrob. Agent Chemother. 38:1386-1391.
3. Bray, M. 2003. Pathogenesis and potential antiviral therapy for complications of smallpox vaccination. Antivir. Res. 58:101-114.
4. Bray, M., M. Martinez, D. F. Smee, D. Kefauver, E. Thompson, and J. W. Huggins. 2000. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 181:10-19.
5. Breman, J. G., and I. Arita. 1980. The confirmation and maintenance of small pox eradication. N. Engl. J. Med. 303:1263-1273.
6. Byrd, C. M., T. C. Bolken, A. M. Mjalli, M. N. Arimili, R. C. Andrews, R. Rothlein, T. Andrea, M. Rao, K. L. Owens, and D. E. Hruby. 2004. New class of orthopoxvirus antiviral drugs that block viral maturation. J. Virol. 78:12147-12156.
7. Ciesla, S. L., J. Trahan, W. B. Wan, J. R. Beadle, K. A. Aldern, G. R. Painter, and K. Y. Hostetler. 2003. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antivir. Res. 59:163-171.
8. Cihlar, T., E. S. Ho, D. C. Lin, and A. S. Mulato. 2001. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 20:641-648.
9. Cihlar, T., D. C. Lin, J. B. Pritchard, M. D. Fuller, D. B. Mendel, and D. H. Sweet. 1999. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol. Pharmacol. 56:570-580.
10. Cundy, K. C. 1999. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. 36:127-143.
11. Cundy, K. C., B. G. Petty, J. Flaherty, P. E. Fisher, M. A. Polis, M. Wachsman, P. D. Lietman, J. P. Lalezari, M. J. M. Hitchcock, and H. S. Jaffe. 1995. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 39:1247-1252.
12. D'Argenio, D. Z., and A. Schumitzky. 1979. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput. Programs Biomed. 9:115-134.
13. DeBroe, M. E., L. Verbist, and G. A. Verpooten. 1991. Influence of dosage schedule on renal accumulation of amikacin and tobramycin in man. J. Antimicrob. Chemother. 27(Suppl. C):41-47.
14. De Clercq, E. 2001. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin. Microbiol. Rev. 14:382-397.
15. De Clercq, E. 2002. Cidofovir in the treatment of poxvirus infections. Antivir. Res. 55:1-13.
16. Deng, L., P. Dai, A. Ciro, D. F. Smee, H. Djaballah, and S. Shuman. 2007. Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virus assembly. J. Virol. 81:13392-13402.
17. Drusano, G. L., J. A. Bilello, S. L. Preston, E. O'Mara, S. Kaul, S. Schnitman, and R. Echols. 2001. Hollow fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. J. Infect. Dis. 183:1126-1129.
18. Drusano, G. L., P. A. Bilello, W. T. Symonds, D. S. Stein, J. McDowell, A. Bye, and J. A. Bilello. 2002. Pharmacodynamics of abacavir in an in vitro hollow-fiber model system. Antimicrob. Agents Chemother. 46:464-470.
19. Earl, P. L., N. Cooper, S. Wyatt, B. Moss, and M. W. Carroll. 1998. Preparation of cell cultures and vaccinia virus stocks, p. 16.16.1-16.16.3. In F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.), Current protocols in molecular biology, vol. 2. John Wiley and Sons, New York, NY.
20. Gowda, S. D., B. S. Stein, K. S. Steimer, and E. G. Engleman. 1989. Expression and processing of human immunodeficiency virus type 1 gag and pol genes by cells infected with a recombinant vaccinia virus. J. Virol. 63:1451-1454.
21. Keith, K. A., M. J. M. Hitchcock, W. A. Lee, A. Holy, and E. R. Kern. 2003. Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication. Antimicrob. Agents Chemother. 47:2193-2198.
22. Keith, K. A., W. B. Wan, S. L. Ciesla, J. B. Beadle, K. Y. Hostetler, and E. R. Kern. 2004. Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro. Antimicrob. Agents Chemother. 48:1869-1871.
23. Kern, E. R. 2003. In vitro activity of potential anti-poxvirus agents. Antivir. Res. 57:35-40.
24. Lacy, S. A., M. J. M. Hitchcock, W. A. Lee, P. Tellier, and K. C. Cundy. 1998. Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in Cynomolgus monkeys. Toxicol. Sci. 44:97-106.
25. Magee, W. C., K. A. Aldern, K. Y. Hostetler, and D. H. Evans. 2008. Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand. Antimicrob. Agents Chemother. 52:586-597.
26. Magee, W. C., K. Y. Hostetler, and D. H. Evans. 2005. Mechanism of inhibition of vaccinia virus DNA polymerases by cidofovir diphosphate. Antimicrob. Agents Chemother. 49:3153-3162.
27. Mahy, B. W. J. 2003. An overview of the use of a viral pathogen as a bioterror agent: why smallpox? Antivir. Res. 57:1-5.
28. Neyts, J., P. Leyssen, E. Verbeken, and E. DeClercq. 2004. Efficacy of cidofovir in a murine model of disseminated progressive vaccinia. Antimicrob. Agents Chemother. 48:2267-2273.
29. Preston, S. L., P. J. Piliero, J. A. Bilello, D. S. Stein, W. T. Symonds, and G. L. Drusano. 2003. In vitro-in vivo model for evaluating the antiviral activity of amprenavir in combination with ritonavir administered at 600 and 100 milligrams, respectively, every 12 hours. Antimicrob. Agents Chemother. 47:3393-3399.
30. Quenelle, D. C., D. J. Collins, and E. R. Kern. 2004. Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir. Antivir. Res. 63:33-40.
31. Quenelle, D. C., D. J. Collins, W. B. Wan, J. R. Beadle, K. Y. Hostetler, and E. R. Kern. 2004. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 48:404-412.
32. Quenelle, D. C., D. J. Collins, B. P. Herrod, K. A. Keith, J. Trahan, J. R. Beadle, K. Y. Hostetler, and E. R. Kern. 2007. Effect of oral treatment with hexadecyloxypropyl-[( S)-9-(3-hydroxy-2- phosphonlymethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice. Antimicrob. Agents Chemother. 51:3940-3947.
33. Quenelle, D. C., M. N. Prichard, K. A. Keith, D. E. Hruby, R. Jordan, G. R. Painter, A. Robertson, and E. R. Kern. 2007. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob. Agents Chemother. 51:4118-4124.
34. Reeves, P. M., Bommarius, S. Lebeis, S. McNulty, J. Christensen, A. Swimm, A. Chahroudi, R. Chavan, M. B. Feinberg, D. Veach, W. Bornmann, M. Sherman, and D. Kalman. 2005. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat. Med. 11:731-739.
35. Rybak, M. J., B. J. Abate, S. L. Kang, M. J. Ruffing, S. A. Lerner, and G. L. Drusano. 1999. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob. Agents Chemother. 43:1549-1555.
36. Sauerbrei, A., C Meier, A. Meerbach, M. Scheil, B. Helbig, and P. Wutzler. 2005. In vitro activity of cycloSal-nucleoside monophosphates and polyhyroxycarboxylates against orthopoxviruses. Antivir. Res. 67:147-154.
37. Smee, D. F., K. W. Bailey, and R. W. Sidwell. 2003. Comparative effects of cidofovir and cyclic HPMPC on lethal cowpox and vaccinia virus respiratory infections in mice. Chemotherapy 49:126-131.
38. Smee, D. F., K. W. Bailey, M. H. Wong, and R. W. Sidwell. 2001. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antivir. Res. 52:55-62.
39. Smee, D. F., and R. W. Sidwell. 2003. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antivir. Res. 57:41-52.
40. Smee, D. F., R. W. Sidwell, D. Kefauver, M. Bray, and J. W. Huggins. 2002. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob. Agents Chemother. 46:1329-1335.
41. Smee, D. F., M.-H. Wong, K. W. Bailey, J. R. Beadle, K. Y. Hostetler, and R. W. Sidwell. 2004. Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice. Int. J. Antimicrob. Agents 23:430-437.
42. Smith, G. L., and G. McFadden. 2002. Smallpox: anything to declare? Nat. Rev. Immunol. 2:521-527.
43. Stittelaar, K. J., J. Neyts, L. Naesens, G. van Amerongen, R. F. van Lavieren, A. Holy, E. De Clercq, H. G. M. Niester, E. Fries, C. Mass, P. G. H. Mudler, B. A. M. van der Zeijst, and A. M. E. Osterhaus. 2006. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature 439:745-748.
44. Wood, C. A., D. R. Norton, S. J. Kohlhepp, P. W. Kohmen, G. A. Porter, D. C. Houghton, R. E. Brummett, W. M. Bennett, and D. N. Gilbert. 1998. The influence of tobramycin dosing regimens on nephrotoxicity and antibacterial efficacy in a rat model of subcutaneous abscess. J. Infect. Dis. 158:113-122.
45. Yang, G., D. C. Pevear, M. H. Davies, M. S. Collett, T. Bailey, S. Rippen, L. Barone, C. Burns, G. Rhodes, S. Tohan, J. W. Huggins, R. O. Baker, R. L. M. Buller, E. Touchette, K. Waller, J. Schriewer, J. Neyts, E. DeClercq, K. Jones, D. Hruby, and R. Jordan. 2005. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79:13139-13149.